Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer

Medicine (United States)

Volumn 94, Issue 22, 2015, Pages e903-

  He, Jiaxi ^a   Shen, Jianfei ^a   Yang, Chenglin ^a   Jiang, Long ^a   Liang, Wenhua ^a   Shi, Xiaoshun ^a   Xu, Xin ^a   He, Jianxing ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM; UFT; VINBLASTINE; VINDESINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; LUNG RESECTION; MORTALITY;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; HUMANS; LUNG NEOPLASMS; PNEUMONECTOMY;

EID: 84941006700     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000903     Document Type: Review

References (37)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
3. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719-727.
4. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559.
5. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-2597.
6. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
7. Group NM-aC, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable nonsmall-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267-1277.
8. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043-5051.
9. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539-1558.
10. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
11. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
12. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
13. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatinbased chemotherapy in resected lung cancer. J Clin Oncol. 2010;28:35-42.
14. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010;28:29-34.
15. Endo C, Saito Y, Iwanami H, et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer. 2003;40:181-186.
16. Imaizumi M. Study Group of Adjuvant Chemotherapy for Lung C. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer. 2005;49:85-94.
17. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713-1721.
18. Nakagawa K, Tada H, Akashi A, et al. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA nonsmall cell lung cancer. Br J Cancer. 2006;95:817-821.
19. Nakagawa M, Tanaka F, Tsubota N, et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)-the 4th study. Ann Oncol. 2005;16:75-80.
20. Niiranen A, Niitamo-Korhonen S, Kouri M, et al. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol. 1992;10:1927-1932.
21. Park JH, Lee CT, Lee HW, et al. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2005;27:1086-1091.
22. Roselli M, Mariotti S, Ferroni P, et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study. Int J Cancer. 2006;119:955-960.
23. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003;95:1453-1461.
24. Wada H, Miyahara R, Tanaka F, et al. Postoperative adjuvant chemotherapy with PVM (Cisplatin Vindesine Mitomycin C) and UFT (Uracil Tegaful) in resected stage I-II NSCLC (nonsmall cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg. 1999;15:438-443.
25. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173-182.
26. A randomized trial of postoperative adjuvant chemotherapy in nonsmall cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Eur J Surg Oncol. 1995;21:69-77.
27. Park SY, Lee JG, Kim J, et al. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. J Cardiothorac Surg. 2013;8:151.
28. Wells GA SB, O'Connell D, Peterson J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.2004Available at: http://www.ohri.ca/programs/clinical- epidemiology/oxford.asp.
29. Mineo TC, Ambrogi V, Corsaro V, et al. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg. 2001;20:378-384.
30. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
31. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
32. NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 3.2014. http://www.nccn.com. Accessed May 1, 2014.
33. Azzoli CG, Temin S, Aliff T, et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol. 2011;29:3825-3831.
34. Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25:1475-1484.
35. Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 (suppl 7): vii56-vii64.
36. Rossi A, Chiodini P, Sun JM, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014;15:1254-1262.
37. Fujii S, Kitano S, Ikenaka K, et al. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gan. 1979;70:209-214.